Help prevent VTE in patients undergoing hip and knee replacement

The identity of you and your healthcare facility will be kept confidential. Only non-identifying information may be used.

As a partner of World Thrombosis Day, the Physician-Patient Alliance for Health & Safety (PPAHS) asks you complete this survey to help better understand and develop practical solutions to prevent VTE in patients undergoing hip and knee replacement.

PPAHS has had a long interest in preventing venous thromboembolism, and has brought together panels of health experts to develop the OB VTE Safety Recommendations and the Stroke VTE Safety Recommendations (both of which are free resources on the PPAHS website).

Hip and knee replacement surgeries are among the most commonly performed procedures in the US. About 1 million of these procedures are performed each year (for more on prevalence, see the study by Hilal Maradit-Kremers, MD, MSc et al, “Prevalence of Total Hip (THA) and Total Knee (TKA) Arthroplasty in the United States”).

The 30-day readmission rate following hip and knee replacement is 4.3% and 3.9% respectively. The readmission rate rises to 7.8% 90-days after surgery.

According to the US Department of Health & Human Services (HSS) Venous Thromboembolism (VTE) (6.3%) is the third most prevalent factor accounting for readmission 30-days after surgery.

By completing this survey, in Question 12, you may elect to be entered into a lottery draw for a chance to win a $100 Amazon gift certificate and to receive a copy of the survey report. The winner of the lottery draw will be chosen randomly from those who complete the survey and the contact information form below.
 
Please complete this survey by 5pmET November 14, 2016.

Question Title

* 1. Please describe your healthcare facility:

Question Title

* 2. I am a (please check that which best describes your daily profession):

Question Title

* 3. Which best describes your primary work setting?: (please specify any specialty – check all that apply)

Question Title

* 4. Do you assess patients undergoing a knee or hip replacement for the risk of VTE? (please check all that apply)

Question Title

* 5. Post-surgery, to prevent DVT, do you (please check all that apply):

Question Title

* 6. On discharge, to prevent DVT, do you (please check all that apply):

Question Title

* 7. CMS under the Joint Replacement bundle reimburses physicians for pharmacological prophylaxis, such as low-molecular-weight heparin (LMWH), and for mechanical prophylaxis, such as intermittent pneumatic compression device (IPCD). However, upon hospital discharge, Medicare Part B does not cover the prescription of IPCD. Do you believe that this is in the best interest of the health of the patient?

Question Title

* 8. Currently with no Medicare Part reimbursement, how likely are you to prescribe the use of IPCD for your Medicare patients for post discharge prevention therapy?

  1 - Least Likely 2 3 4 5 - Most Likely N/A
Likelihood

Question Title

* 9. If Medicare Part B reimbursed for IPCD, how likely would you prescribe the use of IPCD for your Medicare patients for post discharge prevention therapy?

  1 - Least Likely 2 3 4 5 - Most Likely N/A
Likelihood

Question Title

* 10. Upon discharge from hospital following an orthopedic procedure, to prevent incidence VTE, on a scale of 1 (least likely) to 5 (most likely), do you believe that patients are adherent to your recommendation for use of:

  1 - Least Likely 2 3 4 5 - Most Likely
Pharmacological prophylaxis, such as warfarin
Mechanical prophylaxis, such as an IPCD

Question Title

* 11. What do you believe would help better assess and treat patients for VTE (please check all that apply)

T